Background--There is paucity of knowledge concerning the specific age in youth when the associations of metabolic syndrome (MetS) begin to be operative. Thus, we investigated the relation of age to the associations of childhood MetS with adult MetS, type 2 diabetes mellitus and high carotid intima-media thickness.
M
etabolic syndrome (MetS) is a constellation of metabolically interrelated variables, including obesity, hypertension, dyslipidemia, hyperglycemia, and, in some analyses, also including hyperinsulinemia. 1 It is well known that adults with MetS are at increased risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). 2 The potential importance of childhood MetS has been outlined in a consensus statement from the American Heart Association 3 that noted the need for additional research in children and adolescents in order to clarify its relation to the development of adult cardiovascular risk and disease. 3 Defining the age when childhood metabolic risk exposure begins to be associated with adult cardio-metabolic risk and atherosclerosis would help focus pediatric caregivers on preventive strategies, including evaluation and intervention. Using longitudinal data from a collaborative study, we have previously shown a relation between pediatric MetS and adult MetS, T2DM, and high carotid artery intima-media thickness (cIMT), a subclinical marker of atherosclerosis. 4 However, the study did not consider the specific age or ages in youth when the association begins to be operative or whether overweight alone in childhood predicts adult outcomes differentially according to age of measurement.
In the present study, we used data from 5803 individuals in 4 large, prospective cohort studies participating in the International Childhood Cardiovascular Cohort (i3C) Consortium 5 that have followed participants from childhood into adulthood. The objective of the study is to examine the age in childhood when the relationship of childhood MetS and overweight (according to childhood MetS criteria) is first associated with adult MetS, T2DM, and cIMT. Because there is no standard definition for pediatric MetS, we compared 3 previously published definitions. 4, 6 Methods Detailed study characteristics and methods of the 4 cohorts are described elsewhere. These previous reports also include analyses of loss to follow-up to show that the representativeness of the cohorts was maintained. Each study was approved by the appropriate institutional review boards, and written informed consent or assent was obtained from all the study participants aged >18 or assent and consent from their parents for participants aged <18.
Data from more than 1 age (maximum, 1 visit per participant per age group) were entered into the childhood analyses from the 5803 participants (eg, in YFS, a participant examined at age 6, 9, and 12 years had data entered into the analyses from all 3 ages). For subjects with multiple follow-up visits in adulthood, data from the most recent visit were used to maximize the length to follow-up.
Details of the methods used for the measurement of weight, height, blood pressure (BP), lipid levels, glucose and insulin levels, cIMT, and other covariates in each cohort study are provided elsewhere. 5, [7] [8] [9] [10] [11] [12] Height and weight were measured at all time points. Body mass index (BMI) was calculated from the formula: weight (kg)/height (m) 2 . A random zero sphygmomanometer was used to measure BP. Venous blood samples were taken after a 12-hour fast from the antecubital vein. In YFS at baseline, serum cholesterol and triglycerides were measured using fully enzymatic Boehringer CHOD-PAP kits with an OLLI 3000 analyzer. Subsequently, Olympus System reagent analyzer in a clinical chemistry analyzer (AU400; Olympus, Tokyo, Japan) was used to determine lipid levels. Serum high-density lipoprotein (HDL) cholesterol was measured by the dextran sulphate 500 000 method. Lowdensity lipoprotein cholesterol was calculated using the Friedewald formula. 13 In BHS, HDL-cholesterol and triglycerides were measured using chemical procedures with a Technicon Auto Analyzer II (Technicon Instrument Corp, Tarrytown, NY), according to the laboratory manual of the Lipid Research Clinics program. Since this time, these variables were determined by enzymatic procedures 14 using the Abbott VP instrument (Abbott Laboratories, North Chicago, IL). In PLRS data, all serum lipid measurements were performed with standard methods in Centers for Disease Control and Prevention-standardized laboratories. 15 Childhood glucose levels were measured with an ABA-100 system by using the hexokinase method. In adulthood, glucose levels were measured with a Dade Dimension Xpand system by using the hexokinase/glucose-6-phosphate dehydrogenase method. 15, 16 In IS, serum lipids were analyzed in the University of Minnesota laboratory with a Cobas FARA. HDLcholesterol was determined after precipitation of non-HDL lipoproteins with a magnesium/dextran precipitating reagent.
Clinical Perspective
What Is New?
• The data from this study provide help to inform the timing for initiating clinical screening of cardiovascular risk factors.
What Are the Clinical Implications?
• Evaluation of metabolic risk factor levels provide meaningful prediction of adult outcomes around the time of puberty onset.
• Using body mass index alone provides essentially similar results compared to the conventional metabolic syndrome model.
Triglycerides were determined with a standard glycerol blanked enzymatic triglyceride method. Blood samples were analyzed for glucose with a Beckman Glucose Analyzer II (Beckman Instruments Inc, Fullerton, CA). Insulin samples were determined with a radioimmunoassay kit (Equate RIA; Binax Corp, Portland, ME). B-mode ultrasound studies of the left carotid artery were performed at follow-ups using standardized protocols in each study. In YFS, to assess intraindividual reproducibility of ultrasound measurements, 57 subjects were re-examined 3 months after the initial visit. The average absolute difference and SD between measurements was 0.05AE0.04 mm. In BHS, 75 participants underwent repeat ultrasound examinations 10 to 12 days after their initial visit to determine intraindividual reproducibility. The average absolute difference and SD between measurements for all cIMT segments was 0.05AE0.03 mm. In IS, reproducibility of the cIMT showed a mean difference (AESD) of 0.02AE0.03 for analysis separated by 1 week. Table 1 lists the components and values for the 3 MetS definitions used in this study. BMI was used as the measure of adiposity because waist circumference was not available at baseline in all cohorts. Fasting insulin was used when glucose was not available for the YFS, BHS, or IS cohorts at baseline. We generated age-, sex-, race-, cohort-, and study-yearspecific percentiles of BMI, systolic and diastolic BPs, HDLcholesterol, triglycerides, insulin, and glucose. For the modified National Cholesterol Education Program (MetSNCEP75) definition, a participant was categorized as having MetS if he or she had any 3 of the following 5 components: BMI or waist circumference ≥75th percentile; systolic or diastolic BP ≥75th percentile; HDL-cholesterol ≤25th percentile; triglycerides ≥75th percentile; or insulin/ glucose ≥75th percentile.
Definition of MetS and Its Components in Childhood
The second childhood MetS definition used age-and sexstandardized pediatric cut points available in the literature to denote each component risk factor (MetSPed). 4 and high triglycerides were defined using cut points proposed from growth-curve data that were linked to adult definitions. 19 Hyperglycemia was defined as plasma glucose ≥5.60 mmol/L (100 mg/dL). 20 Hyperinsulinemia was defined when glucose was unavailable as having insulin levels above age-, sex-, race-, study-cohort-, and study-yearspecific 75th percentile.
The third MetS definition (MetSCook) was described by Cook et al 21 using the National Cholesterol Education
Program (Adult Treatment Panel III) definition modified for age. Overweight or obesity and elevated BP was defined as BMI or systolic or diastolic BP ≥90th percentile. Elevated values for triglycerides were defined at levels at or above 1.695 mmol/L (150 mg/dL) and for glucose levels at or above 5.6 mmol/L (100 mg/dL); decreased levels of HDLcholesterol were defined as levels at or below 1.036 mmol/L (40 mg/dL). When glucose was not available, we used hyperinsulinemia (≥90th percentile). Finally, a continuous MetS score for children was constructed based on a sex-and race-specific algorithm derived from confirmatory factor analysis of data from the National Health and Nutrition Examination Survey. 22 Participants with missing glucose data were excluded from the continuous MetS analyses. 
Definition of High cIMT in Adulthood
Consistent with previous reports, 24 high cIMT in adulthood was defined as a maximum cIMT ≥90th percentile for age-, sex-, race-, study-year-, and study-cohort-specific values (YFS, BHS). For IS, high cIMT in adulthood was defined as a mean value ≥90th percentile (age, sex, race, and study year) because maximum values were not available. Data on cIMT were not available for the PLRS cohort and were excluded from the analyses examining high cIMT.
Statistical Analysis
The YFS cohort examined children from specific birth cohorts with 3-year intervals (ages 3, 6, 9, 12, 15, and 18 years at baseline survey), whereas the other studies had participants varying across all ages from 3 to 18 years. Therefore, dictated by YFS being the largest cohort, individuals from BHS, PLRS, and IS at age groups of 3 to 4, 5 to 7, 8 to 10, 11 to 13, 14 to 16, and 17 to 18 years were included in the respective age groups with the 3-, 6-, 9-, 12-, 15-, and 18-year-olds from YFS. To take into account possible differences attributed to age, sex, race, and secular trends in risk factors, study cohort, and different methodology age-, sex-, race-, study-year-, and study-cohortspecific risk factor percentiles were generated for childhood risk factors. Age-and sex-adjusted ANOVA for continuous variables and logistic regression for categorical variables was used to compare characteristics among the study groups. For main analyses, different multivariate techniques (Poisson regression with time offset, multinomial regression, Cox proportional hazards ratios, and logistic regression) were used to calculate risk ratios (RR) and 95% confidence intervals (95% CI). Conclusions drawn from the results were essentially similar independent of the method used. In the Results section, the values from the logistic regression are shown, which had the lowest Akaike and Bayesian criterion information values. All regression analyses using data from both sexes were adjusted with sex and all regression models combining data from several cohorts were additionally adjusted for study cohort, and year to minimize the effect of heterogeneity of the participants attributed to geography and physiology. Because of almost no T2DM events were observed in the 2 youngest age groups, we collapsed these 2 groups (3-4 and 5-7 year olds) into 1 age group (3-7 year olds) when analyzing future risk of T2DM.
Statistical analyses were performed with SAS software (version 9.4; SAS Institute, Cary, NC). Statistical significance was inferred as P<0.05. Table 2 shows the number of childhood visits in each study cohort and the clinical characteristics of the study subjects. MeanAESD follow-up time was 22.3AE9.5 years. PLRS had the oldest and IS had the youngest participants at adult follow-up. Subjects were predominantly whites (76%) and blacks (24%). Childhood insulin levels, MetSNCEP75, and adulthood MetS did not have significant differences among the groups (P>0.16).
Results

Clinical Characteristics
Otherwise statistically significant differences in clinical characteristics were observed among the study groups (P always <0.05). The normality assumptions of the residuals were assessed by examining histograms of the residuals and normal probability plots. The residuals were normally distributed. Tables 3 and 4 show RRs and 95% CIs (sexes combined and separately, respectively) according to child age (ages 3-18, divided into 3-year intervals) for childhood (Table 5 ). When study cohorts were analyzed separately, the RRs for childhood MetS in predicting adulthood MetS were consistent with Table 3 (results shown in Table 6 ).
Childhood MetS and Overweight Predicting the Risk for Adult MetS
Childhood MetS Predicting the Risk for Adult T2DM
Because of low number of T2DM events, we collapsed 2 youngest age groups (3-4 and 5-7 year olds) into 1 age group (3-7 year olds). Childhood MetS became a significant (Table 9 ). Other MetSNCEP75 risk factors did not show consistent association with adult T2DM. When study cohorts were analyzed separately, the outcome was unreliable, because of almost no outcome events (Table 10 ).
Childhood MetS Predicting the Risk for Adult High cIMT
Childhood MetS measured by all methods predicted adulthood high cIMT 2-to 4-fold in the 11 to 18 age groups. Detailed RR and 95% CI are presented in Table 11 . The results were the same when sexes were analyzed separately (Table 12 ). When BMI was removed from the MetSNCEP75 criteria, the association was no longer statistically significant in the 11 to 16 female age groups (P>0.13). From the MetSNCEP75 risk factors, only high BMI showed consistent association with adult cIMT from the age of 11 onward (Table 13) . High BP was associated with later intima-media thickness at ages 5 to 7, high insulin at ages 11 to 16, and high triglycerides and low HDL cholesterol at ages 14 to 18. When individual cohorts were analyzed (Table 14) , high adult cIMT was predicted only in YFS and BHS for 11-to 18-yearolds.
Childhood Continuous MetS Score Predicting the Risk for Adult MetS, T2DM, and High cIMT
The association between childhood continuous MetS and adulthood outcomes is shown in Table 15 , with the analyses limited to those with childhood glucose data. The results were similar to the 3 MetS methods (ie, significant for adult MetS at all ages and significant for T2DM and cIMT at adolescent ages). When sexes were analyzed separately, prediction of the adult MetS was significant from age 5 onward (RR, 2.14; 95% CI, 1. 
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All models are adjusted for sex, study cohort, and year. CI indicates 95% confidence interval; MetS, metabolic syndrome, RR, risk ratio.
*MetSPed was defined only for subjects aged 6 to 18 years. 
All models are adjusted for sex, study cohort, and year. BMI indicates body mass index; CI, 95% confidence interval; MetS, metabolic syndrome; RR, risk ratio. *MetSPed was defined only for subjects aged 6 to 18 years. 
All models are adjusted for sex, study cohort, and year. BMI indicates body mass index; BP, blood pressure; CI, 95% confidence interval; HDL, high-density lipoprotein; MetS, metabolic syndrome; RR, risk ratio. *High BMI, BP, insulin, triglycerides ≥age, sex, race, study cohort, and year-specific 75th percentile and low HDL ≤25th percentile. 
Discussion
The results from this study demonstrate that childhood MetS and overweight in both males and females seems to predict increased risk for adult MetS from age 5 years onward. In addition, childhood MetS identifies children from ages 8 to 14 years onward who are at increased risk for adult T2DM and early subclinical atherosclerosis measured by cIMT. Similar results were found when an MetS score, using MetS components as continuous variables, was substituted for the MetS, which uses dichotomized components to define risk. We and others have assessed pediatric MetS as a risk factor for adult MetS, T2DM, and high cIMT in cohorts consisting of both children and adolescents. A prospective study of former students from the Princeton lipid research study reported that children aged 5 to 19 years with MetS were more likely to have MetS, T2DM, and clinical CVD 25 to 30 years later as adults. 10, 25 Similar associations were observed in the YFS and BHS studies concerning MetS, T2DM, and cIMT. 4, 6 However, the number of participants in those studies was too small to be able to consider agestratified analyses, and little is currently known about the age when childhood MetS exposure begins to relate to adult risk. The present study, with a cohort of 5803 individuals, shows that a significant relation between childhood MetS and adult MetS begins as early as age 5 (our data at earlier ages are sparse and we therefore do not consider them definitive), and the relation for T2DM and subclinical atherosclerosis begins in early adolescence. In contrast to the present study, a 10-year longitudinal study of 1604 Pima Indians aged 5 to 19 years with data obtained at age 26 years showed that clustering of CVD risk factors in 3 childhood age groups (5-9, 10-14, and 15-19 years) increased the risk for early T2DM. 26 The slightly younger age at which a relation to adult T2DM was recognized may be related to the known increased risk for development of diabetes mellitus in the Pima population. A standard universal method for defining pediatric MetS is not available, and the criteria currently used have been variably adopted from adult standards. 3 In the present report, we show that the results between 3 different pediatric MetS definitions were essentially similar in predicting adult MetS, T2DM, and cIMT. In addition, the cMetS score, using risk factors as continuous variables, resulted in findings similar 
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All models are adjusted for sex, study cohort, and year. CI indicates 95% confidence interval; MetS, metabolic syndrome; RR, risk ratio; T2DM, type 2 diabetes mellitus. *Because oflow number of outcomes, 2 youngest age groups were collapsed into 1 age group. High BMI, BP, insulin, triglycerides ≥age, sex, race, study cohort, and year-specific 75th percentile and low HDL ≤25th percentile. All models are adjusted for sex, study cohort, and year. BMI indicates body mass index; BP, blood pressure; CI, 95% confidence interval; HDL, high-density lipoprotein; MetS, metabolic syndrome; RR, risk ratio; T2DM, type 2 diabetes mellitus. *Because of low number of outcomes, 2 youngest age groups were collapsed into 1 age group. 
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Models adjusted for sex. BHS indicates the Bogalusa Heart Study; CI, 95% confidence interval; IS, the Insulin Study; MetS, metabolic syndrome; PLRS, the Princeton Lipid Research Study; RR, risk ratio; T2DM, type 2 diabetes mellitus; YFS, the Cardiovascular Risk in Young Finns Study.
*Because oflow number of outcomes, 2 youngest age groups were collapsed into 1 age group.
(slightly greater discrimination, but harder for clinicians to use) to the MetS definitions. In a previous report from YFS, the prediction of adult T2DM and high cIMT using continuous MetS scores in youth was no different to a dichotomous MetS definition. 6 However, among overweight adolescents, it has been observed that the best model for predicting increased cIMT was the sum of the quantitative components of MetS whereas the use of dichotomized MetS variable reduced the predictive accuracy. 27 Concerning the prediction of metabolic risk factors, the results from the IS study have suggested that compared to the dichotomous MetS definition, a continuous MetS score at the age of 13 years provides more-reliable prediction of young adult risk of MetS at the age of 22 years. 28 The present data suggest that a combined evaluation of metabolic risk factor levels provides meaningful prediction of adult outcomes especially after the age of 11 years, that is, around the time of the puberty onset. Based on the present age-stratified analyses, we observe that using BMI alone provides essentially similar results compared with the conventional MetS model. We have previously shown in YFS and BHS data that MetS-binary or continuous-does not seem to contain any additive information beyond the sum of its components, and it usually does not perform any better in predicting cardiometabolic risk than BMI alone. 4, 6 Compared with these previous articles, we now have data from additional cohorts, with bigger sample size, and more case numbers. Therefore, we were able to perform age-stratified analyses. We found that there is not an age in youth when MetS outperforms BMI, given that the present data show that a single assessment of BMI significantly predicts adult outcomes (MetS, T2DM, and high cIMT) at the same age points compared with MetS. In addition to tracking of childhood overweight into adulthood, 29 possible explanation for why high BMI alone predicted adult outcomes similar to MetS in the present study was that BMI is more accurate than measurements of other components of MetS. It has also been shown that excess adiposity may precede the development of other risk factors. 4, 30 Another explanation may be attributed to the complex nature of overlapping pathophysiological mechanisms between the components of MetS. 31 Furthermore, childhood MetS has shown to have marked short-and long-term instability in the categorical diagnosis. 3, 4, 32 
<0.0001
All models are adjusted for sex, study cohort, and year. CI indicates 95% confidence interval; cIMT, carotid intima-media thickness; MetS, metabolic syndrome; RR, risk ratio.
*MetSPed was defined only for subjects aged 6 to 18 years. All models are adjusted for sex, study cohort, and year. BMI indicates body mass index; CI, 95% confidence interval; cIMT, carotid intima-media thickness; MetS, metabolic syndrome; RR, risk ratio. *MetSPed was defined only for subjects aged 6 to 18 years. 
High BMI, BP, insulin, triglycerides ≥ age, sex, race, study cohort, and year-specific 75th percentile and low HDL ≤25th percentile. All models are adjusted for sex, study cohort, and year. BMI indicates body mass index; BP, blood pressure; CI, 95% confidence interval; cIMT, carotid intima-media thickness; HDL, high density lipoprotein; MetS, metabolic syndrome; RR, risk ratio. suggest that universal lipid screening in children should be started between ages 9 to 11 years and testing for fasting glucose among high-risk individuals at younger ages. The guidelines further suggest that MetS should not be considered as a separate entity in childhood or adolescence. 33 Our data are in concert with this recommendation. On the basis of this study, there seems to be no particular age range in childhood at which BMI measurements were not associated with subsequent cardiometabolic outcomes, but MetS would provide significant prediction. This study had some potential limitations. First, waist circumference could not be used as a component of the MetS, because it was not collected at baseline in any of these cohorts. However, BMI previously has been shown to give similar results as waist circumference. 22, 34 Second, heterogeneity in the methodology and especially cIMT location and ultrasound protocols existed between the cohorts. Thus, we attempted to take this heterogeneity into account by harmonizing our data for clinical characteristics 5 and defining risk factors according to age-, sex-, race-, study-year-, and study-specific values. cIMT data were available only among 3 of the cohorts and none of them had measurements available from childhood. Therefore, we were not able to analyze longitudinal cIMT data. However, we have previously shown in the YFS cohort that MetS also identifies young adults with accelerated cIMT progression between 2 time points. 35 Because the study participants were comprised of whites and blacks, the results cannot be directly generalized to other races or ethnic groups. Because of categorical age structure of the YFS and other cohorts, age could not be included as a continuous regression variable in the present study, thus limiting the ability to assess differences within the ages included in these groups. Finally, it should be noted that the power to evaluate associations at the youngest ages was low, because only the YFS and BHS study specifically included children <5 years. The main strength of this study is the vast database from all 4 studies that included similar lifestyle and biological risk factors in childhood and followed the cohorts into adulthood.
In conclusion, this study addresses the utility of MetS in youth outlined in the scientific statement from the American Heart Association 3 by providing information on the age at which childhood MetS begins to identify individuals at increased risk of developing adult CVD. On the basis of our results, adult MetS can be predicted beginning at least as young as age 5, and T2DM and cIMT at or after 8 to 14 years of age. However, the predictions obtained from the status of overweight alone were equivalent to childhood MetS definitions. Therefore, in a pediatric setting, BMI measurements alone seem to provide an easy and informative measure of subsequent cardiometabolic risk.
Disclosures
None. Data are lacking for 3-to 4-year-olds because of missing glucose data in YFS, BHS, and IS cohorts. All models are adjusted for sex, study cohort, and year. RR values are for 1-SD change in MetS score. CI indicates confidence interval; cIMT, carotid intima-media thickness; MetS, metabolic syndrome; RR, risk ratio; T2DM, type 2 diabetes mellitus. *n=Number of events in adulthood, N=Number subjects in each age group with available data in adulthood.
